Skip to main content

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.17
+3.90 (1.90%)
AAPL  271.96
+5.78 (2.17%)
AMD  215.76
+19.16 (9.75%)
BAC  50.65
-0.42 (-0.83%)
GOOG  311.06
-0.63 (-0.20%)
META  639.34
+2.09 (0.33%)
MSFT  386.59
+2.12 (0.55%)
NVDA  193.21
+1.66 (0.87%)
ORCL  145.23
+3.92 (2.77%)
TSLA  405.18
+5.35 (1.34%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.